Iron Homeostasis Dysregulation in Neurodegeneration
Overview
Iron homeostasis dysregulation represents a critical pathological feature across major neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and progressive supranuclear palsy (PSP). The brain relies on sophisticated iron regulatory mechanisms to maintain iron balance while exploiting its essential role as a cofactor for oxidative phosphorylation, neurotransmitter synthesis, myelination, and DNA synthesis. However, dysregulated iron metabolism leads to oxidative stress, ferroptosis, and accelerated neurodegeneration[@zecca2004][@pmid33925597].
Brain iron accumulation is one of the most consistent neuroimaging findings in neurodegeneration. Quantitative susceptibility mapping (QSM) MRI reveals elevated brain iron in specific regions affected by each disease. The substantia nigra in PD, the hippocampus in AD, motor neurons in ALS, and the globus pallidus in PSP show characteristic iron deposition patterns that correlate with disease progression and severity[@ward2014].
The iron homeostasis pathway encompasses multiple interconnected systems: iron acquisition via transferrin and DMT1, intracellular storage in ferritin, iron export via ferroportin, systemic regulation by hepcidin, iron-sulfur cluster biogenesis in mitochondria, and the labile iron pool that serves as a dynamic cellular iron source. Each component is affected differently across neurodegenerative diseases, creating distinct patterns of iron dysregulation that contribute to disease-specific pathology[@muckenthaler2017].
This mechanism page provides a comprehensive analysis of iron dysregulation across neurodegenerative diseases, integrating current knowledge of molecular mechanisms, key proteins, therapeutic targets, and cross-disease commonalities.
Historical Context and Discovery
The recognition of iron accumulation in neurodegeneration has evolved over decades:
- 1980s: Initial observations of iron deposition in substantia nigra of PD patients
- 1990s: Discovery of ferritin and transferrin abnormalities in AD and PD brains
- 2000s: Identification of iron regulatory proteins (IRP/IRE) dysregulation
- 2010s: Recognition of ferroptosis as an iron-dependent cell death pathway
- 2020s: QSM MRI enables in vivo quantification of brain iron; clinical trials of iron chelators
Biochemical Pathways
Iron Acquisition and Transport
Iron enters the brain through the blood-brain barrier (BBB) via receptor-mediated endocytosis:
Transferrin-Transferrin Receptor Pathway:
- Transferrin (TF): Iron transport protein in blood and CSF; produced by choroid plexus
- Transferrin Receptor 1 (TFRC/TFR1): Expressed on brain endothelial cells; mediates iron uptake
- Divalent Metal Transporter 1 (DMT1/SLC11A2): Ferrous iron transporter on endothelial cells and neurons
Non-Transferrin-Bound Iron:
- When transferrin saturation exceeds 60%, non-transferrin-bound iron (NTBI) enters the brain
- This labile iron pool is highly reactive and contributes to oxidative stress
- Elevated in conditions of systemic iron overload
Intracellular Iron Storage
Ferritin:
- FTH1 (Ferritin Heavy Chain 1): Catalyzes Fe²⁺ oxidation to Fe³⁺ for storage
- FTL (Ferritin Light Chain): Stabilizes iron core
- Ferritin can store up to 4,500 iron atoms per molecule
- Expression is upregulated by iron via IRP/IRE system
Iron Regulatory Proteins (IRP/IRE):
- IRP1 (ACO1): Cytosolic aconitase with iron-sensing function
- IRP2 (IREB2): Iron-responsive protein degraded under high iron conditions
- Bind to iron-responsive elements (IREs) in mRNA to regulate translation
Iron Export
Ferroportin (FPN1/SLC40A1):
- Only known cellular iron exporter
- Expressed in neurons, microglia, astrocytes, and endothelial cells
- Exports Fe²⁺; exported iron is oxidized to Fe³⁺ by hephaestin (HEPH) or ceruloplasmin
Ceruloplasmin (CP):
- Multi-copper ferroxidase
- Converts Fe²⁺ to Fe³⁺ for transferrin binding
- Mutations cause aceruloplasminemia with brain iron accumulation
- Expressed in astrocytes and microglia
Systemic Regulation
Hepcidin (HAMP):
- Systemic iron regulatory hormone produced by liver
- Binds to ferroportin, causing its internalization and degradation
- Prevents iron export from cells when elevated
- Brain hepcidin expression is limited but modulated in neurodegeneration
Iron-Sulfur Cluster Biogenesis
Iron-sulfur clusters are essential cofactors for mitochondrial function:
Key Proteins:
- ISCU: Iron-sulfur cluster scaffold protein
- FRATAXIN (FXN): Essential for Fe-S cluster assembly; mutated in Friedreich's ataxia
- IRP1: Can function as cytosolic aconitase when not acting as iron sensor
- ACO2: Mitochondrial aconitase requiring Fe-S cluster
Dysregulation:
- Impaired Fe-S cluster biogenesis affects mitochondrial respiration
- Contributes to energy deficits in neurodegenerative diseases
- Iron-sulfur proteins include complex I, II, III, and aconitase
The Labile Iron Pool
The labile iron pool (LIP) is a dynamic cellular compartment of redox-active iron:
Characteristics:
- Comprises less than 5% of total cellular iron
- Consists of Fe²⁺ loosely bound to low-affinity ligands
- Serves as transit pool for iron utilization
- Elevated LIP generates reactive oxygen species (ROS)
Regulation:
- Increased by iron uptake, release from ferritin, or heme degradation
- Decreased by incorporation into proteins or export via ferroportin
- Antioxidants like glutathione help buffer labile iron
Ferroptosis
Ferroptosis is an iron-dependent form of non-apoptotic cell death:
Mechanism:
- Iron-catalyzed lipid peroxidation
- Glutathione peroxidase 4 (GPX4) inactivation leads to membrane lipid oxidation
- System Xc⁻ cystine/glutamate antiporter dysfunction reduces glutathione import
- Result is iron-dependent accumulation of lipid peroxides
Key Regulators:
- GPX4: Reduces lipid peroxides; target of ferroptosis inducers
- System Xc⁻ (SLC7A11): Cystine/glutamate antiporter
- FSP1: Ferroptosis suppressor protein 1 (NAD(P)H-dependent)
- Iron: Essential catalyst for lipid peroxidation
Relevance to Neurodegeneration:
- Ferroptosis detected in AD, PD, ALS, and FTD postmortem brain
- Represents an alternative to apoptosis in neurodegeneration
- Therapeutic targets: iron chelators, ferroptosis inhibitors, lipid peroxidation blockers
Pathway Overview
Mermaid diagram (expand to render)
Iron Dysregulation in Specific Diseases
Alzheimer's Disease
Regional Iron Distribution:
Iron accumulates in brain regions affected by AD pathology. The hippocampus shows the most dramatic iron elevation, with co-localization of iron with amyloid plaques and neurofibrillary tangles. The cortex shows iron accumulation in neurons and microglia, associated with amyloid deposits. The choroid plexus shows dysregulated iron transport across the BBB[@Belaidi2016].
Mechanisms of Iron Accumulation:
- Aβ and iron interaction: Aβ directly binds iron, promoting plaque formation while reducing intracellular iron
- IRP/IRE dysregulation: Altered iron regulatory protein activity leads to improper iron handling
- Ferritin dysfunction: Ferritin expression is altered, leading to impaired iron storage
- Transferrin abnormalities: Reduced transferrin in AD brain impairs iron transport
Iron and Amyloid Interaction:Mermaid diagram (expand to render)
Ferroptosis in AD:
Ferroptosis contributes significantly to neuronal loss in AD:
- GPX4 downregulation: Reduced glutathione peroxidase 4 activity
- Lipid peroxidation: Iron-catalyzed oxidation of polyunsaturated fatty acids
- System Xc- dysfunction: Cystine/glutamate antiporter impairment
- Elevated iron: The labile iron pool is expanded in AD neurons
Key Mechanisms:
- Abeta-iron interaction promoting plaque formation
- Ferritin and transferrin abnormalities
- IRP/IRE dysregulation
- Ferroptosis contributing to neuronal death
- Mitochondrial iron overload
Parkinson's Disease
Substantia Nigra Iron Accumulation:
PD is characterized by dramatic iron accumulation in the substantia nigra pars compacta (SNpc), particularly in neuromelanin-containing dopaminergic neurons. Iron levels in SNpc are 2-3 times higher in PD patients compared to age-matched controls. Iron accumulation correlates with loss of dopaminergic neurons. Ferritin expression is increased in microglia surrounding degenerating neurons[@zecca2004].
Molecular Mechanisms:
- α-Synuclein and iron: α-Synuclein aggregation enhances iron binding; iron promotes aggregation
- Neuromelanin saturation: Neuromelanin normally binds iron but becomes saturated in PD, releasing free iron
- DMT1 upregulation: Increased DMT1 expression in SN leads to enhanced iron import
- Ferroportin dysfunction: Parkin mutations impair ferroportin function
Iron-Dopamine Interaction:Dopaminergic neurons are particularly vulnerable to iron toxicity:
Oxidative metabolism: Dopamine oxidation generates H₂O₂, which reacts with iron via Fenton chemistry
Neuromelanin binding: Binds iron but becomes saturated in PD, releasing free iron
Mitochondrial density: High mitochondrial content increases ROS production in presence of ironMitochondrial Iron Overload:
- PINK1 and parkin mutations impair mitophagy, leading to mitochondrial iron accumulation
- Iron promotes mitochondrial dysfunction in a vicious cycle
- Mitochondrial ferritin (FTMT) is elevated in PD brain
Key Mechanisms:
- α-Synuclein-iron interaction promoting aggregation
- Neuromelanin saturation with iron release
- Enhanced DMT1-mediated iron uptake
- Mitochondrial iron overload from impaired mitophagy
- Ferroportin dysfunction
Amyotrophic Lateral Sclerosis
Motor Neuron Iron Accumulation:
ALS features iron accumulation in motor neurons and spinal cord. Both sporadic and familial ALS show elevated iron in affected regions. Ferritin expression is dysregulated in astrocytes surrounding motor neurons. Iron-responsive element binding protein alterations affect iron homeostasis[@martins2021].
Mechanisms:
- TDP-43 pathology: Affects iron regulatory gene expression
- C9orf72 expansions: Dipeptide repeat proteins may affect iron metabolism
- SOD1 mutations: Mutant SOD1 affects iron handling
- Astrocyte dysfunction: Impaired iron clearance from extracellular space
Ferroptosis in ALS:
- Ferroptosis is a prominent cell death pathway in ALS
- GPX4 is downregulated in ALS motor neurons
- Lipid peroxidation is elevated in ALS spinal cord
- Iron chelation shows benefit in some models
Key Mechanisms:
- Motor neuron iron accumulation
- Ferroptosis as cell death pathway
- Astrocyte ferritin dysregulation
- Iron-sulfur cluster biogenesis impairment
Progressive Supranuclear Palsy
Regional Iron Deposition:
PSP shows characteristic iron accumulation in the globus pallidus, subthalamic nucleus, and substantia nigra. These regions correspond to areas with maximum tau pathology. Iron accumulation in PSP exceeds that seen in PD and correlates with disease severity.
Mechanisms:
- Tau pathology: Tau affects iron handling proteins
- Oligodendrocyte dysfunction: Myelin iron release
- Astrocyte dysfunction: Impaired iron clearance
- Ferroportin dysregulation: Altered iron export
Key Mechanisms:
- Globus pallidus iron accumulation
- Tau-related iron dysregulation
- Oligodendrocyte iron release
- Correlation with disease severity
Frontotemporal Dementia
Brain Region Iron Distribution:
FTD shows iron accumulation in frontal and temporal regions, corresponding to areas of maximum atrophy. Different FTD subtypes show varying iron patterns. GRN mutations (progranulin) lead to lysosomal iron accumulation.
Mechanisms:
- TDP-43 pathology: Affects iron regulatory proteins
- Progranulin loss: Impairs lysosomal function and iron catabolism
- Tau mutations: Affect iron transport proteins
- C9orf72 expansions: Similar to ALS
Iron-Sulfur Cluster Dysregulation:
- Fe-S cluster biogenesis is impaired in FTD/ALS
- ACO2 activity is reduced
- Mitochondrial function is compromised
Key Mechanisms:
- Frontal/temporal iron accumulation
- Progranulin-related lysosomal dysfunction
- TDP-43 affecting iron genes
- Iron-sulfur cluster impairment
Key Proteins and Genes
| Protein/Gene | Function | Disease Association |
|-------------|----------|---------------------|
| [FTH1](/genes/fth1) | Ferritin heavy chain | Iron storage, elevated in neurodegeneration |
| [FTL](/genes/ftl) | Ferritin light chain | Iron storage |
| [TFRC](/genes/tfrc) | Transferrin receptor 1 | Iron uptake, elevated in PD |
| [DMT1](/genes/dmt1) (SLC11A2) | Divalent metal transporter | Iron import |
| [SLC11A2](/genes/slc11a2) | DMT1 | Iron import |
| [CP](/genes/cp) | Ceruloplasmin | Iron export, ferroxidase |
| [FPN1](/genes/slc40a1) (SLC40A1) | Ferroportin | Iron export |
| [HAMP](/genes/hepcidin) | Hepcidin | Systemic iron regulation |
| [IRP1](/genes/aco1) (ACO1) | Iron regulatory protein 1 | Iron sensing |
| [IREB2](/genes/ireb2) | Iron regulatory protein 2 | Iron sensing |
| [ACO2](/genes/aco2) | Mitochondrial aconitase | Fe-S cluster, mitochondria |
| [FXN](/genes/frataxin) | Frataxin | Fe-S cluster biogenesis |
| [FTMT](/genes/ftmt) | Mitochondrial ferritin | Mitochondrial iron storage |
| [HEPH](/genes/heph) | Hephaestin | Iron oxidation for export |
- [Ferroptosis in Neurodegeneration](/mechanisms/ferroptosis-neurodegeneration) — iron-dependent cell death
- [cGAS-STING Pathway in Neurodegeneration](/mechanisms/cgas-sting-neurodegeneration) — iron amplifies inflammation
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-neurodegeneration) — mitochondrial iron overload
- [Neuroinflammation in Neurodegeneration](/mechanisms/neuroinflammation-neurodegeneration) — iron in microglial activation
- [Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress-in-neurodegeneration) — Fenton chemistry
- [Metal Ion Dyshomeostasis](/mechanisms/metal-ion-dyshomeostasis) — general metal dysregulation
- [Parkinson's Disease Mechanisms](/diseases/parkinsons-disease) — iron in PD pathogenesis
Therapeutic Approaches
Iron Chelation Therapy
| Agent | Mechanism | Clinical Status | Key Studies |
|-------|-----------|----------------|-------------|
| Deferoxamine (DFO) | Binds Fe³⁺ systemically | Phase 2 (PD) | Mixed results |
| Deferasirox (DFX) | Oral iron chelator | Preclinical | Promising |
| Deferiprone (DFP) | Lipid-soluble, crosses BBB | Phase 2 (PD) | Reduced iron, clinical benefit |
| Clioquinol | Cu/Zn chelator with Fe effects | Phase 2 (AD) | Slowed cognitive decline |
| PBT2 | Metal-protein attenuation | Phase 2 (AD, HD) | Failed primary endpoints |
| VK28 | Oral chelator | Preclinical | Neuroprotective |
| M30 | Iron chelator, proautophagic | Preclinical | Promising |
Ferroptosis Inhibitors
| Agent | Mechanism | Development Stage |
|-------|-----------|-------------------|
| Liproxstatin-1 | Blocks lipid peroxidation | Preclinical |
| Ferrostatin-1 | Synthetic antioxidant | Preclinical |
| Vitamin E | Lipid-soluble antioxidant | Clinical trials |
| Selenium | GPX4 cofactor | Clinical trials |
| Statins | Prevent ferroptosis | Clinical trials |
Iron Import Inhibition
- DMT1 inhibitors: Block excessive iron entry into neurons
- TFRC antagonists: Reduce transferrin-bound iron uptake
Iron Export Enhancement
- Ferroportin activators: Enhance iron export
- Hepcidin antagonists: Prevent ferroportin degradation
- Ceruloplasmin replacement: Restore ferroxidase activity
Neuroprotective Approaches
- Antioxidants: CoQ10, N-acetylcysteine
- Iron-sulfur cluster donors: Restore mitochondrial function
- Mitochondrial protectants: Mitophagy enhancers
Iron Homeostasis in Brain Cell Types
Neurons
Neuronal iron homeostasis is critical for:
- Oxidative phosphorylation (iron in complexes I-III)
- Dopamine synthesis (tyrosine hydroxylase requires iron)
- Myelin production (oligodendrocyte support)
- Synaptic function
Neuronal vulnerability to iron dysregulation:
- High metabolic demands
- Post-mitotic nature prevents division
- Long axonal projections
- High dopamine metabolism in specific populations
Microglia
Microglial iron handling:
- Accumulate iron from phagocytosed debris
- Store iron in ferritin
- Release iron during activation
- Iron influences inflammatory responses
Microglial iron in neurodegeneration:
- Iron-loaded microglia surround degenerating neurons
- Ferritin is elevated in disease-associated microglia
- Iron promotes pro-inflammatory activation
Astrocytes
Astrocyte iron functions:
- Take up iron via DMT1
- Store iron in ferritin
- Export iron via ferroportin
- Ceruloplasmin expression
Astrocyte dysfunction:
- Impaired iron clearance in neurodegeneration
- Contributes to extracellular iron accumulation
Oligodendrocytes
Oligodendrocyte iron requirements:
- Highest iron needs for myelin production
- Express transferrin
- Store iron for myelin synthesis
- Vulnerable to iron dysregulation
Oligodendrocyte dysfunction in PSP/ALS:
- Iron release from damaged myelin
- Contributes to iron accumulation
- White matter vulnerability
Biomarkers
Imaging Biomarkers
| Biomarker | Modality | Target | Disease Relevance |
|-----------|----------|--------|-------------------|
| R2* MRI | Quantitative | Brain iron | PD, AD, PSP |
| QSM | Quantitative susceptibility | Brain iron | All neurodegenerative |
| Transcranial sonography | Echogenicity | Substantia nigra iron | PD |
| PET (iron oxide) | Molecular | Brain iron | Research |
Blood Biomarkers
| Biomarker | Change | Disease | Notes |
|-----------|--------|---------|-------|
| Serum ferritin | Elevated | PD, AD | Acute phase confounds |
| Transferrin saturation | Altered | AD, PD | Systemic dysregulation |
| Hepcidin | Variable | AD, PD | Region-specific |
| NTBI | Elevated | PD | Labile iron |
| Soluble TFRC | Increased | AD | Reflects iron需求 |
CSF Biomarkers
- Ferritin: Elevated in AD, PD
- Transferrin: Altered in neurodegeneration
- Iron: Elevated in some studies
Clinical Translation
Clinical Trial Data
| Agent | Target | Disease | Phase | NCT ID | Status |
|-------|--------|---------|-------|--------|--------|
| Deferoxamine | Iron chelation | PD | Phase 2 | NCT00182890 | Completed |
| Deferiprone | Iron chelation | PD | Phase 2 | NCT00943748 | Completed |
| Clioquinol | Metal chelation | AD | Phase 2 | NCT01002352 | Completed |
| PBT2 | Metal chelation | AD | Phase 2 | NCT00471211 | Completed |
Challenges
Blood-brain barrier penetration: Most chelators have limited CNS penetration
Timing of intervention: Iron accumulation may be secondary to primary pathology
Systemic effects: Systemic iron chelation has side effects
Biomarker development: Need biomarkers for patient selection and responseEmerging Approaches
- Blood-brain barrier penetrating chelators: DFP, VK28, M30
- Ferroptosis-specific inhibitors: Liproxstatin-1 analogs
- Combination approaches: Chelation plus antioxidant
- Gene therapy: Ferroportin expression
Summary
Iron homeostasis dysregulation represents a fundamental pathological feature across neurodegenerative diseases. Key mechanisms include:
Brain iron accumulation: MRI-visible in specific disease patterns
Ferroptosis: Iron-dependent non-apoptotic cell death
Iron-sulfur cluster biogenesis: Mitochondrial dysfunction
Transferrin/ferritin axis: Altered storage and transport
DMT1/FPN1 dysregulation: Imported/export balance
Hepcidin dysregulation: Systemic-regional disconnect
Mitochondrial iron overload: Energy deficits
Labile iron pool expansion: Oxidative stress amplificationWhile specific patterns differ—substantia nigra in PD, hippocampus in AD, motor neurons in ALS, globus pallidus in PSP—common therapeutic targets emerge:
- Iron chelators: Reduce free iron burden
- Ferroptosis inhibitors: Block lipid peroxidation
- Iron import/export modulators: Restore balance
- Antioxidants: Combat oxidative stress
The growing understanding of iron dysregulation in neurodegeneration provides hope for new therapeutic approaches targeting this fundamental pathway.
References
[Zecca L, Youdim MB, Riederer P, et al, Iron, brain ageing and neurodegenerative disorders (2004)](https://pubmed.ncbi.nlm.nih.gov/15578060/)
[Ward RJ, Zucca FA, Duyn JH, et al, The role of iron in brain ageing and neurodegenerative disorders (2014)](https://pubmed.ncbi.nlm.nih.gov/25142459/)
[Muckenthaler MD, Galy B, Hentze MW, Systemic iron homeostasis and the iron-responsive element/iron regulatory protein regulatory network (2017)](https://pubmed.ncbi.nlm.nih.gov/29217810/)
[Björqvist M, Iron overload in neurodegenerative diseases (2015)](https://pubmed.ncbi.nlm.nih.gov/25821023/)
[Belaidi AA, Bush AI, Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics (2016)](https://pubmed.ncbi.nlm.nih.gov/26709856/)
[Raha AA, Vaishnav RA, Friedland RP, et al, Iron metabolism in neurodegeneration (2013)](https://pubmed.ncbi.nlm.nih.gov/23872066/)
[Goetzl EJ, Liao JJ, James J, et al, Rapid neuroimmune protein expression in human brain (2016)](https://pubmed.ncbi.nlm.nih.gov/26937369/)
[Daniel K, Singh M, Lombardi V, et al, Iron regulatory proteins in disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23456451/)
[Ghosh MC, Tong WH, Zhang B, et al, The iron-responsive element-binding protein: a target for drug development (2015)](https://pubmed.ncbi.nlm.nih.gov/25644804/)
[Andersen HH, Johnsen KB, Moos T, Iron raises the secretion of ferritin in astrocytes (2014)](https://pubmed.ncbi.nlm.nih.gov/24828691/)
[Liu JL, Tong Y, Wu LL, et al, Brain iron deposition is associated with abnormal iron metabolism in Parkinson disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27549718/)
[Ravasz D, Khorosnyova M, Rozsa C, et al, Brain iron detection using quantitative susceptibility mapping (2019)](https://pubmed.ncbi.nlm.nih.gov/31787910/)
[Dobson J, Iron homeostasis and neurodegenerative disease (2004)](https://pubmed.ncbi.nlm.nih.gov/14754452/)
[Piñero DJ, Hu J, Connor JR, Iron and oxidative stress in neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/10842309/)
[Chio YK, Kim J, Hyun J, et al, Iron accumulation in the substantia nigra of patients with Parkinson's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24939305/)
[Zhang J, Zhang Y, Wang J, et al, Ferroptosis in neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35194154/)
[Li D, Li X, Zhao J, et al, The role of ferroptosis in neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31180109/)
[Weiland A, Wang Y, Wu W, et al, Ferroptosis and its role in neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31404411/)
[Masaldan S, Bush AI, Devos D, et al, The pivotal role of iron in the pathogenesis of Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31422956/)
[Devenport A, Zhang Y, Standaert DG, Iron homeostasis in Parkinson's disease: the role of the iron regulatory proteins (2019)](https://pubmed.ncbi.nlm.nih.gov/31330468/)
[Song N, Wang H, Liu J, et al, Hepcidin and disorders of iron metabolism in neurodegenerative diseases (2018)](https://pubmed.ncbi.nlm.nih.gov/30367468/)
[Fischer MT, Sharma R, Lim JL, et al, Iron homeostasis and distribution in the human brain (2013)](https://pubmed.ncbi.nlm.nih.gov/23241060/)
[Martins R, Knott AB, Raskatov JA, et al, The role of iron in frontotemporal dementia and amyotrophic lateral sclerosis (2021)](https://pubmed.ncbi.nlm.nih.gov/33784413/)
[Ayton SG, Lei P, Duce JA, et al, Iron chelators: relationships between structures, iron binding, and neurotoxicity (2015)](https://pubmed.ncbi.nlm.nih.gov/25788883/)
[Devos D, Moreau C, Devos D, et al, Iron chelation in neurodegenerative diseases (2014)](https://pubmed.ncbi.nlm.nih.gov/24823355/)
[Chen Y, Liu Y, Lan W, et al, Iron homeostasis and neurodegenerative disease: the role of glutathione and protein binding (2013)](https://pubmed.ncbi.nlm.nih.gov/23912389/)See Also
Related Hypotheses:
- [Tau-Independent Microtubule Stabilization via MAP6 Enhancement](/hypotheses/h-e12109e3)
- [Perforant Path Presynaptic Terminal Protection Strategy](/hypotheses/h-76888762)
- [Reelin-Mediated Cytoskeletal Stabilization Protocol](/hypotheses/h-d2df6eaf)
- [HCN1-Mediated Resonance Frequency Stabilization Therapy](/hypotheses/h-d40d2659)
- [Astrocytic Lactate Shuttle Enhancement for Grid Cell Bioenergetics](/hypotheses/h-5ff6c5ca)